Overview
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed within Vladimir Khavinson's peptide bioregulator research programme at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a "pineal gland bioregulator" — one of a family of very short peptides Khavinson's group designed to mimic naturally occurring tissue-specific regulatory peptides, on the theory that each organ produces its own short peptide signals that decline with age.
It is important to state plainly what the evidence base for Pinealon actually looks like: almost all published research originates from Khavinson's own laboratories or closely affiliated Russian institutions, published largely in Russian-language journals or their English-language sister publications (e.g.
Bulletin of Experimental Biology and Medicine,
Advances in Gerontology). There is no independent Western replication, no registered Western clinical trial, and no regulatory approval for Pinealon as a medicine in the EU, UK, or Ireland. Readers should treat the findings below as a specific, narrow research literature — not as consensus science — and weigh that context heavily.
Within that literature, Pinealon is studied mainly in aged rodent models for effects on brain oxidative stress markers, sleep-wake cycle regulation (linked to its proposed action on melatonin-producing pinealocytes), and general neuroprotection in models of cognitive decline. This guide is for educational and research purposes only. Not medical advice.
Clinical & Research Status
| Evidence Type |
Status |
| Human RCT (Western) |
✗ |
| Human RCT (Russian, small-scale) |
✔ (limited) |
| Animal Studies |
✔ |
| In Vitro |
✔ |
| Regulatory Approval (Ireland/EU) |
✗ |
Mechanism of Action
Pinealon's proposed mechanism is not receptor-based in the way conventional pharmaceuticals are described. Khavinson's peptide bioregulator theory proposes that very short peptides (2-4 amino acids) can interact directly with gene promoter regions or chromatin, modulating transcription of genes relevant to the tissue the peptide is derived from — in this case, pineal tissue. This is a substantially different and far less mechanistically established framework than classical receptor pharmacology.
Preclinical papers from the Khavinson group report that Pinealon has been observed to support reductions in markers of oxidative stress in brain tissue of aged animals, and to has been observed to support normalisation of circadian rhythm markers in models with disrupted sleep-wake cycles. Proposed downstream effects include modulation of antioxidant enzyme activity (e.g. superoxide dismutase, catalase) in neural tissue and effects on melatonin-related signalling. These mechanisms are reported almost exclusively by the originating research group and have not been independently confirmed through Western peer-reviewed replication.
Research Areas & Reported Effects
Sleep-Wake Cycle Regulation
The bulk of Pinealon-specific research relates to circadian and sleep-cycle parameters in aged rodent models, given its classification as a pineal-tissue bioregulator. Reported findings describe improved sleep architecture markers and normalised activity-rest patterns in older animals following Pinealon administration, proposed to relate to pinealocyte function and melatonin regulation.
Neuroprotection and Oxidative Stress
Several Khavinson-affiliated papers report reduced markers of oxidative damage in brain tissue of aged rodents given Pinealon, alongside improved performance on rodent memory and learning tasks (e.g. Morris water maze, passive avoidance). These are presented as evidence for a general neuroprotective and antioxidant profile.
Age-Related Cognitive Decline Models
Pinealon has been studied in rodent models of accelerated ageing (including the SAMP8 mouse strain used in Russian gerontology research) for effects on cognitive performance markers. Reported outcomes describe has been observed to support in learning and memory task performance relative to untreated aged controls.
Research Data Summary
| Study / Model |
Reported Effect |
| Aged Rat Model (Khavinson et al.) |
Reported reduction in brain lipid peroxidation markers and increased antioxidant enzyme activity. |
| SAMP8 Accelerated-Ageing Mouse Model |
Reported improvement in memory task performance relative to untreated aged controls. |
| Rodent Circadian Disruption Model |
Reported normalisation of rest-activity cycle markers. |
| In Vitro Neural Cell Culture |
Reported reduction in oxidative stress markers under induced oxidative challenge. |
Stack Combinations Studied
- Pinealon + Cortagen → Research rationale: Explored in Russian gerontology literature as a combined "CNS-tissue" bioregulator pairing — pineal and cortical bioregulators studied together for broader neuroprotective and cognitive research aims.
- Pinealon + Epithalon → Research rationale: Both associated with pineal/circadian biology in the wider Khavinson bioregulator catalogue; studied together in some longevity-focused Russian protocols for sleep and ageing markers.
⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.
Research Protocol Reference
experimental research protocols only — not dosing recommendations.
| Protocol |
Dose (experimental model only) |
Duration (experimental model only) |
Frequency (experimental model only) |
Research Context |
| Rodent Research Protocol |
Model-dependent, mcg/kg range reported in Russian literature |
10-20 days |
Once daily |
Oxidative stress and cognitive task studies in aged rodents. |
| Russian Small-Scale Human Study Protocol |
Reported as intranasal administration in limited Russian trials |
10-day course |
As per study protocol |
Reported in small Russian clinical research on cognitive and sleep markers; not independently replicated. |
Observed Side Effects in Research
- No significant adverse events reported in the available Khavinson-affiliated literature
- Independent Western safety data is not available
- Long-term human safety data does not exist outside limited Russian research settings
Because independent Western toxicology and safety studies have not been conducted, the absence of reported side effects in the existing literature should not be read as an established safety profile.
Compound Data
- CAS Number
- Not consistently assigned in Western chemical registries
- Molecular Formula
- C14H23N5O8 (Glu-Asp-Arg tripeptide)
- Molecular Weight
- Approximately 389.4 g/mol
- Half-Life
- Not established in independently published pharmacokinetic literature
- Synonyms
- Glu-Asp-Arg, EDR peptide, pineal gland bioregulator peptide
- Research Classification
- Khavinson-class short peptide bioregulator, tissue-specific (pineal/CNS) research peptide
Scientific References
The references below are drawn from Vladimir Khavinson's peptide bioregulator research programme. Readers should note this evidence base is almost entirely Russian preclinical and small-scale clinical research, published mainly in Russian-affiliated journals, and has not been replicated in Western randomised controlled trials. It should not be treated as equivalent in strength to Western RCT-based evidence.
- [Khavinson VK et al. 2011] — Tripeptide Glu-Asp-Arg (Pinealon) has an antioxidant and neuroprotective effect in the brain of old rats. — Bulletin of Experimental Biology and Medicine — [Animal / Russian research programme]
- [Khavinson VK et al. 2012] — Peptide regulation of gene expression and protein synthesis in bronchial epithelium — Advances in Gerontology — [related bioregulator mechanism literature]
- [Umnov RS et al.] — Effect of short peptides on neurodegeneration markers in aged animal models — Russian gerontology literature — [Animal]
- [Khavinson VK, Malinin VV] — Gerontological Aspects of Genome Peptide Regulation — Karger monograph — [Theoretical / mechanistic framework]
*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*